Jardiance for HCM Patients?

A recent study published in the American Journal of Cardiology found that patients with non-obstructive hypertrophic cardiomyopathy and diabetes showed significant improvements to diastolic heart function and BNP (a hormone produced by the body which indicates heart wall stress) from the use of a drug used for diabetes known as a sodium glucose co-transponder 2 inhibitor (SGLT2).  

This class of drugs is commonly used to lower blood sugar in diabetics.  One SGLT2 in common usage is Jardiance (empagliflozin).

Since treatments for non-obstructive HCM patients are so limited, this class of drugs presents a potential treatment opportunity for non-diabetic HCM patients as well. 

Hey all you researchers out there – sounds like a good clinical trial!

Traditional Cardiovascular Risk Factors Worsen HCM

According to this recent article in the European Heart Journal, traditional cardiovascular risk factors such as obesity, hypertension and diabetes are associated with more severe forms of HCM. Therefore, the authors suggest that these additional risk factors should be aggressively managed so as to limit their impact on HCM.